Abstract 2323P
Background
Non-small cell lung cancers (NSCLC) are the leading cause of cancer morbitidy and mortality globally with a 5-year survival of ∼15-20%. Immunotherapies have shown durable benefit in a subset of patients. There is a growing need to identify better biomarkers able to stratify patients who are likely to respond to therapy. Whilst PD-L1 expression and other assessments such as tumour mutation burden (TMB), microsatellite instability (MSI) have shown associations with patient outcomes, there remains a need to comprehensively characterize the tumour microenvironment (TME).
Methods
In this study, we used high-dimensional spatial transcriptome and proteomic profiling of whole slides from NSCLC patients who had received single-agent immunotherapy. We performed a combination of compartmentalized (tumour/stroma) 1800-plex RNA (Nanostring Technologies, Cancer Transcriptome Atlas) and whole-slide 57-plex Phenocycler Fusion and custom Phenocode Signature Panels (Akoya Biosciences) targeting immune contexture, immune profiles, activation status, metabolic activity and immune checkpoints.
Results
For our transcriptome analysis, we compared the tumour and stromal compartments associations with response to therapy (RECIST). The tumour compartments showed specific enrichment for metabolic pathways in patients that were non-responsive to immunotherapy. These findings were further strengthened at the protein level with a grouping of metabolic signatures, including Glucose Transporter 1 (GLUT-1), Glucose-6-phosphate dehydrogenase (G6PD) and Citrase Synthase (CS). In resistant tumours, there was a clear lack of CD8 and CD68 infiltration and reduction or absence of lymphoid/tertiary lymphoid-like structures highlighting the complementarity of T- and B-cell biology in areas of high metabolic activity.
Conclusions
This study identifies a unique metabolic signature associated with response and resistance to immunotherapy in NSCLC which is mirrored by T- and B-cell biology. Our study demonstrates the utility of high-dimensional spatial multi-omic profiling to delineate new signatures associated with response to therapy and aid in patient stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
N. Ma, A. Pratapa, O. Braubach: Financial Interests, Institutional, Full or part-time Employment: Akoya Biosciences. K.J. O'Byrne: Financial Interests, Personal, Other, Advisor/consultant on project development by the company: TriStar; Financial Interests, Personal, Other, Invited speaker; advisory board: BMS; Financial Interests, Personal, Other, Advisory board; invited speaker: AstraZeneca, MSD, Janssen; Financial Interests, Personal, Other, advisory board; invited speaker: Roche; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Takeda; Financial Interests, Personal, Other, Advisory board: Pfizer; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Advisory Board, Advice on development of lasertinib: Yuhan; Financial Interests, Personal, Advisory Board, Advice re cabozantinib: Ipsen; Financial Interests, Personal, Advisory Board, Advice of drug development program: Beigene; Financial Interests, Personal, Invited Speaker, Topic - tepotinib: Merck; Financial Interests, Personal, Other, Sponsorship for travel, accommodation and registration for ESMO Congress, Paris, 2022: Bayer; Financial Interests, Personal, Stocks/Shares, 5% non-dilutable shares in a start-up Pharma company: RepLuca Pharmaceuticals Pty Ltd.; Financial Interests, Personal, Stocks/Shares, Start-up diagnostics focused on genomics: DGC diagnostics; Financial Interests, Personal, Other, Co-founder, Board Member and Share Holder (15%) in the Pharma and biotech company: Carpe Vitae Pharmaceuticals Pty Ltd.; Financial Interests, Personal, Steering Committee Member, Steering Committee Member 2 trials- CA-209-227- CA-224-095: BMS; Financial Interests, Personal, Steering Committee Member, Steering Committee Member LUX-Lung program: Boehringer Ingelheim; Non-Financial Interests, Other, Chair an education session: Foundation Medicine. All other authors have declared no conflicts of interest.
Resources from the same session
2336P - MiR-155 overexpression regulates epithelial-mesenchymal transition through repressing Quaking in lung cancer cells
Presenter: Jung-Jyh Hung
Session: Poster session 16
2337P - Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer
Presenter: Marina Mencinger
Session: Poster session 16
2338P - The phenotype of tumor-associated macrophages in human high-grade serous ovarian carcinoma
Presenter: Irina Larionova
Session: Poster session 16
2339P - Clinical and genomic correlates of plasma circulating tumor DNA (ctDNA) tumor fraction (TF) in patients with advanced NSCLC
Presenter: Filippo Dall'Olio
Session: Poster session 16
2340P - T-cell immunoglobulin and mucin-domain containing molecule-3 (Tim3) in breast cancer and the impact on penetration of blood brain barrier by cancer cells
Presenter: Xiaoshan Cao
Session: Poster session 16
2341P - Novel therapeutic opportunities in metaplastic breast cancer
Presenter: Fresia Pareja
Session: Poster session 16
2342P - Single tumor cells are a novel prognostic criterion in breast cancer patients
Presenter: Liubov Tashireva
Session: Poster session 16
2343P - Evolution of circulating tumour DNA analysis in France over 5 years
Presenter: Guillaume Herbreteau
Session: Poster session 16
2345P - The possibility of programmed death-ligand 1-related immune modulation in neoadjuvant thermoradiotherapy for rectal cancer
Presenter: seihwan you
Session: Poster session 16
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16